Wednesday, October 25, 2017

Patient Connect Alnylam Announcement

October 25, 2017
Alnylam is currently conducting a study with individuals who have acute hepatic porphyria (AHP), including AIP, VP, HCP, or ADP, as well as with caregivers of someone with AHP. The purpose of this study is to receive feedback about a newly developed porphyria electronic diary. Please click here to open a document for more information about this study. 

Please note – It’s important that the participants in this research are not identified to Alnylam. If you are interested in participating, please contact:

Siobhan McDonold
Telephone: 617-612-4053

A phone screen will take place to ensure that eligibility criteria are met before an in-person interview is scheduled. Participants must provide genetic documentation of AHP and have had at least one attack in the last six months. The interview will be conducted in-person, will be approximately 60 minutes long, and will be audio-recorded. Participants will be compensated for their time. Alnylam will not know the names of any participants, and the feedback we receive will be anonymized.

Warm Regards,
Alnylam Pharmaceuticals

No comments:

Post a Comment

What is δ-Aminolevulinic Acid Dehydratase Porphyria (ADP)?

What is δ-Aminolevulinic Acid Dehydratase Porphyria (ADP)? ADP is more severe than the other acute porphyrias and can present in childhoo...